English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Background: Breast cancer is sometimes found after symptoms appear, but many women with breast cancer have no symptoms. This is why regular breast cancer screening is so important, early detection and treatment are the most important strategies to prevent deaths from breast cancer. Breast cancer that’s found early, when it’s small and has not spread, is easier to treat successfully, regular screening tests are the most reliable way for early detection. Objective: to high light the role of sonomammography versus Magnetic Resonance Imaging (MRI) in evaluation of BI-RADS III (Breast Imaging Reporting and Data System) breast lesion. Patients and Methods: in this retrospective study, 28 patients with BI-RADS III breast lesion were assessed by Digital mammography (DM), Ultrasound (US) and MRI. The resultant images were correlated with reports of the pathology specimens. Results: histopathological analysis was done for each lesion with 13 lesions (46.43%) proved to be benign, 15 lesions (53.57%) proved to be malignant. The sensitivity, specificity, Positive predictive value (PPV) and Negative predictive value (NPV) of mammography (MG), ultrasonography and MRI in BI-RADS III breast lesions were calculated. Conclusion: BI-RADS III lesions group is a very critical group to deal with as it exhibits characters of both malignant and benign lesions. According to our study Dynamic contrast enhanced - Magnetic Resonance Imaging. (DCE-MRI) should go hand by hand with sonomammogaphy especially in BI-RADS III patients group, patients with benign looking lesion six months follow up is recommended and those with malignant looking lesion biopsy should be done.

Sonomammography versus MRI in Evaluation of BI-RADS III Breast Lesion